Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion

Pituitary

Volumn 11, Issue 1, 2008, Pages 63-70

  Wu, Zhe Bao ^a   Su, Zhi Peng ^a   Wu, Jin Sen ^a   Zheng, Wei Ming ^a   Zhuge, Qi Chuan ^a   Zhong, Ming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bromocriptine; Cavernous sinus; Dopamine agonist; Empty sella; Invasive prolactinoma; Optic chiasmal herniation

Indexed keywords

BROMOCRIPTINE; PROLACTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CANCER CONTROL; CANCER INVASION; CANCER RECURRENCE; CAVERNOUS SINUS; CEREBROSPINAL FLUID FISTULA; CEREBROVASCULAR ACCIDENT; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESISTANCE; DRUG WITHDRAWAL; EMPTY SELLA SYNDROME; FATIGUE; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SIDE EFFECT; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BROMOCRIPTINE; CAVERNOUS SINUS; CHEMOTHERAPY, ADJUVANT; DOPAMINE AGONISTS; EMPTY SELLA SYNDROME; FEMALE; FOLLOW-UP STUDIES; HERNIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROSURGERY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OPTIC CHIASM; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 38649116343     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0072-4     Document Type: Article

References (39)

1. Cottier JP, Destrieux C, Brunereau L et al (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463-469
2. Knosp E, Steiner E, Kitz K et al (1993) Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610-618
3. Wu ZB, Yu CJ, Su ZP et al (2006) Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: Results of a long-term follow up. J Neurosurg 104(1):54-61
4. Delgrange E, Sassolas G, Perrin G, et al (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochirurgica (Wien) 147:751-758
5. Delgrange E, Duprez T, Maiter D (2006) Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol 64:456-462
6. Laws ER Jr, Thorner MO, Vance ML (1996) Bromocriptine therapy for prolactin-secreting pituitary adenomas. Neurosurg Focus 1(1):E4
7. Colao A, Di-Sarno A, Landi ML et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574-3579
8. Essais O, Bouguerra R, Hamzaoui J et al (2002) Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol (Paris) 63(6 Pt 1):524-531
9. Shrivatava RK, Arginteanu MS, King WA et al (2002) Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97:299-306
10. Yu C, Wu Z, Gong J (2005) Combined treatment of invasive giant prolactinomas. Pituitary 8(1):61-65
11. Couldwell WT, Weiss MH, Rabb C et al (2004). Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: Surgical experience in 105 cases. Neurosurgery 55:539-550
12. Losa M, Mortini P, Barzaghi R et al (2002) Surgical treatment of prolactin-secreting pituitary adenomas: Early results and long-term outcome. J Clin Endocrinol Metab 87:3180-3186
13. Sieck JO, Niles NL, Jinkins JR et al (1986) Extrasellar prolactinomas: successful management of 24 patients using bromocriptine. Horm Res 23(3):167-176
14. van't Verlaat JW, Croughs RJ, Hendriks MJ et al (1990) Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension. Can J Neurol Sci 17(1):71-73
15. Delgrange E, Maiter D, Donckier J (1996) Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 134:454-456
16. Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 84(7):2518-2522
17. Fraioli B, Esposito V, Santoro A et al (1995) Transmaxillosphenoidal approach to tumors invading the medial compartment of the cavernous sinus. J Neurosurg 82:63-69
18. Frank G, Pasquini E (2006) Endoscopic endonasal cavernous sinus surgery, with special reference to pituitary adenomas. Front Horm Res 34:64-82
19. Hashimoto N, Kikuchi H (1990) Transsphenoidal approach to infrasellar tumors involving the cavernous sinus. J Neurosurg 73:513-517
20. Jho HD, Carrau RL (1997) Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 87(1):44-51
21. Kitano M, Taneda M (2001) Extended transsphenoidal approach with submucosal posterior ethmoidectomy for parasellar tumors. Technical note. J Neurosurg 94:999-1004
22. Sabit I, Schaefer SD, Couldwell WT (2000) Extradural extranasal combined transmaxillary transsphenoidal approach to the cavernous sinus: A minimally invasive microsurgical model. Laryngoscope 110:286-291
23. Landolt AM, Lomax N (2000) Gamma knife radiosurgery for prolactinomas. J Neurosurg 93(Suppl 3):14-18
24. Pan L, Zhang N, Wang EM et al (2000) Gamma Knife radiosurgery as a primary surgical treatment for prolactinomas. J Neurosurg 93(suppl 3):10-13
25. Pouratian N, Sheehan J, Jagannathan J et al Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59:255-266
26. Petrovich Z, Yu C, Giannotta SL et al Gamma knife radiosurgery for pituitary adenoma: Early results. Neurosurgery 53:51-59
27. Pollock BE, Nippoldt TB, Stafford SL et al (2002) Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: Factors associated with endocrine normalization. J Neurosurg 97:525-530
28. Shin M, Kurita H, Sasaki T et al (2000) Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus. J Neurosurg 93(suppl 3):2-5
29. Laws ER Jr, Vance ML (1999) Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin North Am 10:327-336
30. Morange-Ramos I, Regis J, Dufour H et al (1998) Gamma-knife surgery for secreting pituitary adenomas. Acta Neurochir (Wien) 140(5):437-443
31. Johnston DG, Hall K, Kendall-Taylor P et al (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas: Studies with highdefinition computerised tomography. Lancet 2:187-192
32. Wang C, Lam KSL, Ma JT et al (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: Effect of drug withdrawal. Clin Endocrinol (Oxf) 27:363-371
33. Zarate A, Canales ES, Cano C et al Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 104:139-142
34. Passos VQ, Souza JJS, Musolino NRC et al (2002) Long-term follow-up of prolactinomas: Normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578-3582
35. Colao A, Di-Sarno A, Cappabianca P et al (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349(21):2023-2033
36. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313(11):656-659
37. Moriondo P, Travaglini P, Nissim M et al (1985) Bromocriptine treatment of microprolactinomas: Evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60:764-772
38. van't Verlaat JW, Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: Effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34:175-178
39. Jones SE, James RA, Hall K et al (2000) Optic chiasmal herniation-an under recognized complication of dopamine agonist therapy for macroprolactinoma. Clin Endocrinol (Oxf) 53(4):529-534